DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Frequently asked questions
What sector does DBV Technologies S.A. (DBV) operate in?
DBV Technologies S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is DBV Technologies S.A. (DBV) current stock price?
As of the latest data, DBV Technologies S.A. stock price is €2.39, with a previous close of €2.41. DBV Technologies S.A. lost -€0.03 in the last trading session, representing a -1.16% loss.
What is DBV Technologies S.A. (DBV) current market capitalization?
DBV Technologies S.A. market cap is approximately 706.11 million.
What is DBV Technologies S.A. (DBV) Earnings Per Share (EPS)?
The trailing EPS is -€0.61, and the forward EPS is -€0.15.
What is DBV Technologies S.A. (DBV) EBITDA?
DBV Technologies S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -41.24 million.
Does DBV Technologies S.A. (DBV) pay dividends?
No. DBV Technologies S.A. does not pay a dividend.
When is DBV Technologies S.A. (DBV) next earnings report?
DBV Technologies S.A. is expected to release its next earnings report on September 30, 2026.
What is DBV Technologies S.A. (DBV) beta (volatility) score?
DBV Technologies S.A. has a beta of -0.212, indicating lower volatility than the overall market.
